Tech Company Financing Transactions
Eisbach Funding Round
Eisbach, based in Planegg, secured $4.5 million from Cancer Focus Fund.
Transaction Overview
Company Name
Announced On
3/21/2024
Transaction Type
Venture Equity
Amount
$4,500,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to to support a Phase 1/2 clinical trial of its lead candidate, EIS-12656, which will be conducted at MD Anderson.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Am Klopferspitz 19
Planegg, 82152
Germany
Planegg, 82152
Germany
Phone
Undisclosed
Website
Email Address
Overview
We are a pioneering precision oncology company focused on genome reorganization. Eisbach enables the potential of synthetic lethality by exploiting the unique molecular vulnerabilities present in validated cancer targets. Our ALLOS platform systematically recapitulates the tight controls that strictly regulate the activity of our cancer-driving molecular machines. We exploit this regulation to develop targeted allosteric therapies for chromatin reorganization.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adrian Schomburg
VP - Finance
Jonathan Iorio
Browse more venture capital transactions:
Prev: 3/21/2024: Form Energy venture capital transaction
Next: 3/21/2024: Radia venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs